See more : RF Industries, Ltd. (RFIL) Income Statement Analysis – Financial Results
Complete financial analysis of Edesa Biotech, Inc. (EDSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Edesa Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- World Of Wireless International Telecom, Inc. (WWII) Income Statement Analysis – Financial Results
- AksharChem (India) Limited (AKSHARCHEM.NS) Income Statement Analysis – Financial Results
- Orzel Bialy S.A. (OBL.WA) Income Statement Analysis – Financial Results
- Searchlight Resources Inc. (SCLTF) Income Statement Analysis – Financial Results
- Otco International Limited (OTCO.BO) Income Statement Analysis – Financial Results
Edesa Biotech, Inc. (EDSA)
About Edesa Biotech, Inc.
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 328.80K | 410.87K | 211.85K | 228.29K | 1.27M | 758.69K | 372.13K | 545.47K | 286.05K | 697.19K | 854.84K | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 183.47K | 118.19K | 118.79K | 17.60K | 101.29K | 445.32K | 534.45K | 1.13M | 840.25K | 760.26K | 576.53K | 436.40K | 1.01M | 386.09K | 0.00 | 0.00 |
Gross Profit | 0.00 | -183.47K | -118.19K | -118.79K | 311.20K | 309.58K | -233.47K | -306.17K | 143.86K | -81.56K | -388.13K | -31.06K | -150.35K | -311.90K | 468.75K | 0.00 | 0.00 |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 94.65% | 75.35% | -110.21% | -134.11% | 11.31% | -10.75% | -104.30% | -5.69% | -52.56% | -44.74% | 54.83% | 0.00% | 0.00% |
Research & Development | 2.88M | 4.79M | 13.34M | 17.95M | 3.33M | 1.10M | 2.09M | 1.97M | 1.73M | 1.03M | 2.46M | 1.45M | 1.83M | 906.52K | 352.78K | 0.00 | 0.00 |
General & Administrative | 4.13M | 4.43M | 5.04M | 5.73M | 3.38M | 2.05M | 2.76M | 2.94M | 3.32M | 3.23M | 2.87M | 2.24M | 4.43M | 5.84M | 1.15M | 78.50K | 0.00 |
Selling & Marketing | 0.00 | -183.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 4.13M | 4.24M | 5.04M | 5.73M | 3.38M | 2.05M | 2.76M | 2.94M | 3.32M | 3.23M | 2.87M | 2.24M | 4.43M | 5.84M | 1.15M | 78.50K | 0.00 |
Other Expenses | 0.00 | 0.00 | -780.26K | -10.34M | 37.41K | 0.00 | 0.00 | 0.00 | 24.63K | 0.00 | 0.00 | 0.00 | 112.14K | 87.33K | 30.37K | 0.00 | 0.00 |
Operating Expenses | 7.01M | 9.22M | 17.59M | 13.34M | 6.71M | 3.14M | 4.84M | 4.92M | 5.05M | 4.26M | 5.33M | 3.65M | 6.37M | 6.83M | 1.53M | 78.50K | 0.00 |
Cost & Expenses | 7.01M | 9.22M | 17.59M | 13.34M | 6.73M | 3.24M | 5.29M | 5.45M | 6.18M | 5.10M | 6.09M | 4.22M | 6.81M | 7.84M | 1.92M | 78.50K | 0.00 |
Interest Income | 153.50K | 289.85K | 63.52 | 11.17K | 37.78K | 56.84K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.99K | 4.88K | 11.30K | 2.80K | 4.64K | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.73K | 58.00 | 0.00 |
Depreciation & Amortization | 186.05K | 183.47K | 118.19K | 118.79K | 57.56K | 6.37K | 188.37K | 179.32K | 149.57K | 159.52K | 158.31K | 124.83K | 112.14K | 87.33K | 13.27K | 4.70K | 0.00 |
EBITDA | -6.13M | -8.19M | -17.43M | -13.22M | -6.35M | -2.83M | -4.85M | -4.85M | -4.87M | -2.65M | -8.25M | -3.72M | -6.43M | -3.51M | -761.82K | -64.65K | 0.00 |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,946.72% | -687.79% | -2,327.12% | -2,295.32% | -363.58% | -752.80% | -770.26% | 1,404.04% | -2,703.14% | -1,010.13% | -122.75% | 0.00% | 0.00% |
Operating Income | -7.01M | -9.22M | -18.37M | -23.68M | -6.40M | -2.83M | -5.08M | -5.22M | -4.91M | -4.34M | -5.72M | -3.68M | -6.52M | -7.10M | -1.07M | -78.56K | 0.00 |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,946.72% | -689.30% | -2,397.11% | -2,288.59% | -385.97% | -571.85% | -1,536.69% | -674.37% | -2,280.23% | -1,018.37% | -124.63% | 0.00% | 0.00% |
Total Other Income/Expenses | 845.50K | 849.14K | 822.67K | 10.34M | 37.41K | -309.45K | 40.10K | 194.70K | -110.52K | 1.53M | -2.78M | -11.21M | 1.37M | 3.50M | 477.02K | 4.64K | 0.00 |
Income Before Tax | -6.17M | -8.37M | -17.55M | -13.34M | -6.36M | -2.78M | -5.04M | -5.03M | -5.02M | -2.81M | -8.41M | -14.89M | -5.20M | -7.09M | -588.37K | -73.92K | 0.00 |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,935.34% | -675.82% | -2,378.18% | -2,203.30% | -394.66% | -369.88% | -2,260.58% | -2,728.98% | -1,816.40% | -1,016.27% | -68.83% | 0.00% | 0.00% |
Income Tax Expense | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | -55.40K | 800.00 | 800.00 | 7.20K | 36.80K | 27.20K | 800.00 | 800.00 | 800.00 | 1.60K | 0.00 | 0.00 |
Net Income | -6.17M | -8.37M | -17.55M | -13.34M | -6.36M | -2.72M | -5.04M | -5.03M | -5.03M | -2.84M | -8.44M | -14.89M | -5.20M | -7.09M | -589.97K | -73.92K | 0.00 |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,935.59% | -662.33% | -2,378.56% | -2,203.65% | -395.23% | -374.73% | -2,267.88% | -2,729.12% | -1,816.68% | -1,016.39% | -69.02% | 0.00% | 0.00% |
EPS | -1.93 | -2.93 | -8.37 | -7.74 | -5.18 | -4.15 | -10.54 | -218.72 | -23.92 | -15.01 | -46.75 | -121.14 | -49.86 | -78.14 | -15.88 | -7.67 | 0.00 |
EPS Diluted | -1.93 | -2.93 | -8.37 | -7.73 | -5.18 | -4.15 | -10.54 | -211.28 | -23.92 | -15.01 | -46.75 | -121.14 | -49.86 | -78.14 | -15.88 | -7.67 | 0.00 |
Weighted Avg Shares Out | 3.20M | 2.86M | 2.10M | 1.73M | 1.23M | 655.00K | 478.23K | 23.00K | 210.15K | 189.45K | 180.54K | 122.89K | 104.23K | 90.68K | 37.14K | 9.63K | 9.96K |
Weighted Avg Shares Out (Dil) | 3.20M | 2.86M | 2.10M | 1.73M | 1.23M | 655.32K | 478.23K | 23.81K | 210.15K | 189.45K | 180.54K | 122.89K | 104.23K | 90.68K | 37.14K | 9.63K | 9.96K |
Edesa Biotech's Founder Makes Strategic Investment in the Company
Edesa Biotech Announces Upcoming Conference Schedule
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
Edesa Biotech to Participate in Upcoming Investor Conferences
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
Edesa Biotech to Participate in Barclays Global Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports